Evidence map›Paper›PMID 27557905›Full record

ArticlePaediatric drugs2016

The Cognitive Profile of Ethosuximide in Children.

Dominique M IJff, Tamar M van Veenendaal, Mariette H Debeij-van Hall, Jacobus F A Jansen, Anton J A de Louw, Marian H J M Majoie, Albert P Aldenkamp

Abstract read
PubMed Publisher
In one paragraph

Article in Paediatric drugs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Dominique M IJffDepartment of Behavioural Sciences, Epilepsy Centre Kempenhaeghe, P.O. Box: 61, 5590 A.B., Heeze, The Netherlands. IJffD@kempenhaeghe.nl.
Tamar M van VeenendaalSchool for Mental Health and Neurosciences, Maastricht University, Maastricht, The Netherlands.
Mariette H Debeij-van HallDepartment of Neurology, Epilepsy Centre Kempenhaeghe, Heeze, The Netherlands.
Jacobus F A JansenSchool for Mental Health and Neurosciences, Maastricht University, Maastricht, The Netherlands.
Anton J A de LouwDepartment of Neurology, Epilepsy Centre Kempenhaeghe, Heeze, The Netherlands.
Marian H J M MajoieSchool for Mental Health and Neurosciences, Maastricht University, Maastricht, The Netherlands.
Albert P AldenkampDepartment of Behavioural Sciences, Epilepsy Centre Kempenhaeghe, P.O. Box: 61, 5590 A.B., Heeze, The Netherlands.
Maastricht University Medical Centre · NLKempenhaeghe · NLEindhoven University of Technology · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAlthough ethosuximide is one of the oldest antiepileptic drugs (AEDs), little information is available about the cognitive side effects of ethosuximide.

objectiveThe aim of this study was to investigate the cognitive profile of ethosuximide.

methodsIn this cross-sectional study, we used an extensive neuropsychological test battery in patients with epilepsy aged 6-16 years who were treated with monotherapy ethosuximide. We evaluated the efficacy of the drug by seizure frequency (seizure free or not).

resultsWe included 61 patients with a mean age of 9.4 years [standard deviation (SD) 2.7] who used on average 686 mg/day (SD 245) ESM as monotherapy. ESM was effective in the majority of the patients (70 % were seizure free for at least 6 months at moment of inclusion). The total study population showed impairments of intelligence, visuomotor, and attentional function including activation/alertness. Comparisons between the well-controlled patients and patients who were not in remission showed significantly lower intelligence values and lower performance on the visual-perceptual and attentional tasks for the group with ongoing seizures. Our results suggested that the higher order cognitive dysfunctions (such as intelligence and visual-perceptual functions) may be regarded as seizure or aetiology effects and that the impaired fluid cognitive functions, such as activation/alertness, sustained auditory attention and attentional control or switching, were due to ESM.

conclusionThis study suggests the attentional dysfunction resulting in psychomotor slowing and alertness deficits may be regarded as effects of ethosuximide. Although no untreated baseline assessment was available, these effects are comparable to those of other AEDs, and ethosuximide may therefore be considered an AED with only mild effects on cognition. As ethosuximide is a first-line therapy for absence seizures in childhood, and drug-induced cognitive impairment may interfere with development, learning, and academic achievement, these findings are of interest to clinicians who prescribe this drug, especially when informing parents.

Indexed as

AdolescentAnticonvulsantsChildCognitionCross-Sectional StudiesEpilepsy, AbsenceEthosuximideFemaleHumansMaleRetrospective StudiesSeizuresAnticonvulsantsEthosuximide

Identifiers

PMID27557905
OpenAlexW2513552785

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.